DelveInsight, a leading market research and healthcare consulting company, has released its latest report, “Myotonic Dystrophy Market Insight, Epidemiology, and Market Forecast–2036.” The report provides a comprehensive understanding of Myotonic Dystrophy, including historical and forecasted epidemiology, current and emerging treatment landscape, Myotonic Dystrophy Market Trends, competitive intelligence, and forecasted market dynamics across the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
Key Takeaways from the Myotonic Dystrophy Market
The Myotonic Dystrophy Market Size across the 7MM is expected to grow significantly during the forecast period 2022–2036.
DelveInsight estimates that the Myotonic Dystrophy Market Size will increase from approximately USD 217 million in 2029 to nearly USD 2.6 billion by 2036, reflecting the impact of upcoming innovative therapies and expanding treatment adoption.
In 2025, the total Myotonic Dystrophy Market Size across the 7MM was approximately USD 236 million, with strong growth anticipated throughout the forecast period.
In 2025, the aggregate diagnosed prevalent population of Myotonic Dystrophy across the 7MM was approximately 110,000 cases, highlighting the substantial burden of this rare neuromuscular disorder.
The United States accounted for approximately 57,000 diagnosed prevalent cases in 2025 and represented the largest share of the Myotonic Dystrophy Market among the 7MM.
In 2025, EU4 and the UK collectively accounted for approximately 40,200 diagnosed prevalent cases of Myotonic Dystrophy.
Japan accounted for approximately 13,100 diagnosed prevalent cases in 2025, with Myotonic Dystrophy Type 1 representing the overwhelming majority of cases.
Leading Myotonic Dystrophy companies, including Avidity Biosciences, AMO Pharma, Harmony Biosciences, and Lupin, are actively advancing innovative therapies to strengthen the future Myotonic Dystrophy Industry.
Emerging therapies such as Delpacibart etedesiran (AOC-1001), Tideglusib (AMO-02), and Pitolisant (WAKIX) are expected to reshape the future Myotonic Dystrophy Drug Market.
Keen to know more about the market? Request our sample page for the Myotonic Dystrophy Market.
https://www.delveinsight.com/sample-request/myotonic-dystrophy-market
Key Factors Driving the Myotonic Dystrophy Market
Growing Diagnosed Patient Population and Improved Genetic Testing
Advances in molecular diagnostics and increasing awareness among healthcare professionals are enabling earlier and more accurate diagnosis of Myotonic Dystrophy. Improved genetic testing capabilities are reducing diagnostic delays and contributing to growth in the diagnosed patient population, supporting Myotonic Dystrophy Market Growth.
High Unmet Need for Disease-Modifying Therapies
Currently, no approved therapies can cure or slow disease progression in Myotonic Dystrophy. Existing treatment approaches focus primarily on symptom management through anti-myotonic agents, anti-diabetic medications, NSAIDs, antidepressants, rehabilitative therapies, and supportive devices. The lack of disease-modifying therapies creates substantial opportunities within the Myotonic Dystrophy Treatment Market.
Advancements in RNA-Targeted and Genetic Therapeutics
The development of novel approaches including antisense oligonucleotides, RNA-targeted therapies, antibody oligonucleotide conjugates, and gene-targeted interventions is expected to transform the treatment paradigm. These innovations represent some of the most important Myotonic Dystrophy Market Trends during the forecast period.
Myotonic Dystrophy Competitive Landscape
The current Myotonic Dystrophy treatment landscape primarily consists of symptomatic therapies including antiarrhythmic drugs, antihypertensive drugs, hypolipidemic drugs, anti-diabetic drugs, NSAIDs, and other supportive treatments aimed at improving quality of life and managing multisystem complications.
Among emerging therapies, Delpacibart etedesiran (AOC-1001) from Avidity Biosciences is one of the most promising candidates. The therapy targets the underlying cause of Myotonic Dystrophy Type 1 by reducing disease-associated DMPK mRNA using an antibody oligonucleotide conjugate platform. The therapy is currently being evaluated in the global Phase III HARBOR trial.
Tideglusib (AMO-02) is being investigated for congenital Myotonic Dystrophy and has demonstrated encouraging potential through normalization of GSK3β activity. Pitolisant (WAKIX) is also being studied for excessive daytime sleepiness associated with Myotonic Dystrophy Type 1.
These developments are expected to significantly influence future Myotonic Dystrophy Market Share and strengthen the overall Myotonic Dystrophy Industry outlook.
Discover more about therapies set to grab major Myotonic Dystrophy market share @ Myotonic Dystrophy Treatment LandscapeRecent Developments in the Myotonic Dystrophy Market
In September 2025, AMO Pharma reported preliminary safety results from the ongoing REACHCDM-X open-label extension study evaluating AMO-02 in congenital and childhood-onset Myotonic Dystrophy Type 1.
In April 2025, Avidity Biosciences received Orphan Drug Designation in Japan for Delpacibart etedesiran (del-desiran) for the treatment of Myotonic Dystrophy Type 1.
In July 2025, Avidity Biosciences announced completion of enrollment for the Phase III HARBOR trial evaluating Delpacibart etedesiran and provided guidance regarding regulatory submission plans.
In June 2024, Harmony Biosciences reported positive clinical data demonstrating the efficacy of Pitolisant in managing excessive daytime sleepiness and fatigue in patients with Myotonic Dystrophy Type 1.
In September 2023, AMO Pharma announced positive findings from the REACH-CDM clinical trial evaluating Tideglusib (AMO-02) in Myotonic Dystrophy.
What is Myotonic Dystrophy?
Myotonic Dystrophy is a rare autosomal dominant neuromuscular disorder characterized by progressive muscle weakness, myotonia, and multisystem involvement affecting skeletal muscles, the heart, respiratory system, endocrine organs, and central nervous system. There are two major forms—Myotonic Dystrophy Type 1 (DM1) and Myotonic Dystrophy Type 2 (DM2). DM1 is caused by CTG repeat expansion in the DMPK gene, while DM2 results from CCTG repeat expansion in the CNBP gene. Symptoms may include muscle weakness, excessive daytime sleepiness, cardiac arrhythmias, respiratory complications, cataracts, insulin resistance, and cognitive impairment.
Myotonic Dystrophy Epidemiology Segmentation
The Myotonic Dystrophy epidemiology section provides insights into the historical and current patient population and forecasted trends across the 7MM. The Myotonic Dystrophy Market report offers epidemiological analysis for the study period 2022–2036 segmented into:
Total Diagnosed Prevalent Cases of Myotonic Dystrophy
Type-specific Diagnosed Prevalent Cases of Myotonic Dystrophy
Type-specific Diagnosed Cases of Myotonic Dystrophy Type 1
Age-specific Diagnosed Prevalent Cases of Myotonic Dystrophy
Comorbidity-associated Diagnosed Cases of Myotonic Dystrophy
Scope of the Myotonic Dystrophy Market Report
Therapeutic Assessment: Myotonic Dystrophy current and emerging therapies
Myotonic Dystrophy Market Dynamics: Key Market Forecast Assumptions of Emerging Myotonic Dystrophy Drugs and Market Outlook
Key Companies: Avidity Biosciences, AMO Pharma, Harmony Biosciences, Lupin, Arrakis Therapeutics, and others
Key Therapies: Delpacibart etedesiran (AOC-1001), Tideglusib (AMO-02), Pitolisant (WAKIX), Mexiletine (NaMuscla), and others
Competitive Intelligence Analysis: SWOT Analysis and Market Entry Strategies
Unmet Needs, KOL Views, Analyst Views, Myotonic Dystrophy Market Access and Reimbursement
To know more about Myotonic Dystrophy companies working in the treatment market, visit @ Myotonic Dystrophy Clinical Trials and Therapeutic AssessmentTable of Contents
Myotonic Dystrophy Market Report Introduction
Executive Summary for Myotonic Dystrophy
SWOT Analysis of Myotonic Dystrophy
Myotonic Dystrophy Patient Share (%) Overview at a Glance
Myotonic Dystrophy Market Overview at a Glance
Myotonic Dystrophy Background and Overview
Myotonic Dystrophy Epidemiology and Patient Population
Country-Specific Patient Population of Myotonic Dystrophy
Myotonic Dystrophy Current Treatment and Medical Practices
Myotonic Dystrophy Unmet Needs
Myotonic Dystrophy Emerging Therapies
Myotonic Dystrophy Market Outlook
Country-Wise Myotonic Dystrophy Market Analysis (2022–2036)
Myotonic Dystrophy Market Access and Reimbursement of Therapies
Myotonic Dystrophy Market Drivers
Myotonic Dystrophy Market Barriers
Myotonic Dystrophy Appendix
Myotonic Dystrophy Report Methodology
DelveInsight Capabilities
Disclaimer
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Kirti SharmaEmail: Send EmailPhone: 09650213330Address:304 S. Jones Blvd #2432 City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/
